https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Pharmacogenomic study in patients with multiple sclerosis: responders and nonresponders to IFN-ß https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22647 Wed 22 May 2019 14:51:24 AEST ]]> NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27223 M-H = 0.08). These results point to a role of the NLRP3 inflammasome and its related cytokine IL1B in the response to interferon beta in patients with relapsing-remitting multiple sclerosis.]]> Sat 24 Mar 2018 07:32:24 AEDT ]]> A pharmacogenetic study implicates NINJ2 in the response to Interferon-ß in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38338 -4, hazard ratio = 1.41). Moreover, rs7298096AA is associated with a higher NINJ2 expression in blood (p = 7.0 x 10-6), which was confirmed in vitro (p = 0.009). Finally, NINJ2 expression is downregulated by IFNβ treatment and related to TTFR. Conclusions: Rs7298096 could influence MS disease activity during IFNβ treatment by modulating NINJ2 expression in blood. The gene encodes for an adhesion molecule involved in inflammation and endothelial cells activation, supporting its role in MS.]]> Mon 30 Aug 2021 13:46:38 AEST ]]>